antiviral news

Researchers report the ability of tofacitinib to reduce infection risk with SARS-CoV-2 in individuals who are deficient in PTPN2.

Shionogi will receive $375 million to develop a long-acting protease inhibitor designed to prevent SARS-CoV-2 infection in people who are immune compromised.

After seeing its Covid-19 drug fail in a Phase 3 trial last year, Shionogi on Thursday won a $375 million award from HHS to develop a preventive drug for the disease.

Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announced Shionogi Inc., a New Jersey-based subsidiary of Shionogi, has been awarded a $375 million project agreement through the Rapid Response Partnership Vehicle (RRPV), to advance the development of S-892216, a 3CL protease inhibitor, as a long-acting injectable for COVID-19 pre-exposure prophylaxis.

Extended-course nirmatrelvir/ritonavir yields a meaningful reduction in symptoms for some patients with long COVID, but not all benefits persist, according to a case series published online Jan. 6 in Communications Medicine.

Paxlovid, an antiviral already used against Covid-19, could also offer solutions to patients suffering from long Covid, according to the work of American researchers.